- The approval is based on P-II CITN-09/KEYNOTE-017 study assessing Keytruda in 50 patients with recurrent LA or mMCC who had not received prior systemic therapy
- P-II CITN-09/KEYNOTE-017 study results: ORR 56%; CR 24%; PR 32%; DOR @6 mos./ 12 mos. (96%, 54%); median duration of exposure 6.6 mos.
- Keytruda (pembrolizumab) 100mg IV is a mAb, used as an anti-D-L1 therapy that blocks interaction between PD-1 and its ligands i.e PD-L1 & PD- L2, further activating T lymphocytes
Click here to read full press release/ article | Ref: Merck & Co | Image: The Street